Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genetic Services Laboratory, |
RCV000121242 | SCV002066043 | uncertain significance | not specified | 2021-12-16 | criteria provided, single submitter | clinical testing | DNA sequence analysis of the JAK2 gene demonstrated a sequence change, c.2538G>C, in exon 19 that results in an amino acid change, p.Glu846Asp. This sequence change has been described in the gnomAD database with a frequency of 0.076% in the non-Finnish European subpopulation (dbSNP rs150221602). The p.Glu846Asp change affects a highly conserved amino acid residue located in a domain of the JAK2 protein that is known to be functional. In-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL) provide contradictory results for the p.Glu846Asp substitution. This sequence has been previously described as a germline variant in individuals with myeloproliferative disorders in either the heterozygous or compound heterozygous state (PMID: 30259120, 273897150). An experimental study using a cellular model demonstrated that p.Glu846Asp is a weakly activating mutation (PMID: 273897150). Due to insufficient evidences, the clinical significance of the p.Glu846Asp change remains unknown at this time. |
Labcorp Genetics |
RCV002517591 | SCV003276013 | benign | not provided | 2023-11-25 | criteria provided, single submitter | clinical testing | |
ITMI | RCV000121242 | SCV000085413 | not provided | not specified | 2013-09-19 | no assertion provided | reference population |